What's next in translational medicine?

Clinical Science

Volumn 112, Issue 3-4, 2007, Pages 217-227

  Littman, Bruce H ^a   Di Mario, Linda ^b   Plebani, Mario ^c   Marincola, Francesco M ^d  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b BioAdvance   (United States)

^c UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Clinical research; Drug target; Translational medicine; Translational research

Indexed keywords

CLINICAL RESEARCH; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; HEALTH CARE; HEALTH CARE COST; LITERATURE; NON PROFIT ORGANIZATION; PRIORITY JOURNAL; REVIEW;

ANIMALS; BIOMEDICAL RESEARCH; CHEMISTRY, PHARMACEUTICAL; DRUG EVALUATION; DRUG INDUSTRY; HUMANS; PUBLIC OPINION; RESEARCH SUPPORT;

EID: 33846958355     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20060108     Document Type: Review

References (54)

1. Mankoff, S. P., Brander, C., Ferrone, S. and Marincola, F. M. (2004) Lost in translation: obstacles to translational medicine. J. Transl. Med. 2, 14
2. Marincola, F. M. (2003) Translational medicine: a two way road. J. Transl. Med. 1, 1
3. Davis, D., Evans, M., Jadad, A. et al. (2003) The case for knowledge translation: shortening the journey from evidence to effect. Br. Med. J. 327, 33-35
4. Crowley, Jr, W. F., Sherwood, L., Salber, P. et al. (2004) Clinical research in the United States at a crossroads: proposal for a novel public-private partnership to establish a national clinical research enterprise. JAMA, J. Am. Med. Assoc. 291, 1120-1126
5. Plebani, M. and Laposata, M. (2006) Translational research involving new biomarkers of disease: a leading role for the pathologist. Am. J. Clin. Pathol. 126, 169-171
6. Lehmann, F., Lacombe, D., Therasse, P. and Eggermont, A. M. (2003) Integration of translational research in the European Organization for Research and Treatment of Cancer Research (EORTC) clinical trial cooperative group mechanisms. J. Transl. Med. 1, 2
7. Fontanarosa, P. B. and DeAngelis, C. D. (2002) Basic science and translational research in JAMA. JAMA, J. Am. Med. Assoc. 287, 1728
8. Ioannidis, J. P. (2004) Materializing research promises: opportunities, priorities and conflicts in translational medicine. J. Transl. Med. 2, 5
9. Sung, N. S., Crowley, Jr, W. F., Genel, M. et al. (2003) Central challenges facing the national clinical research enterprise. JAMA, J. Am. Med. Assoc. 289, 1278-1287
10. Fontanarosa, P. B. and DeAngelis, C. D. (2003) Translational medical research. JAMA, J. Am. Med. Assoc. 289, 2133
11. Parks, M. R. and Disis, M. L. (2004) Conflicts of interest in translational research. J. Transl. Med. 2, 28
12. Webb, C. P. and Pass, H. I. (2004) Translation research: from accurate diagnosis to appropriate treatment. J. Transl. Med. 2, 35
13. Carter, R. E. and Woolson, R. F. (2004) Statistical design considerations for pilot studies transitioning therapies from the bench to the bedside. J. Transl. Med. 2, 37
14. Horig, H. and Pullman, W. (2004) From bench to clinic and back: perspective on the 1st IQPC Translational Research conference. J. Transl. Med. 2, 44
15. Horig, H., Marincola, E. and Marincola, F. M. (2005) Obstacles and opportunities in translational research. Nat. Med. 11, 705-708
16. Joiner, K. A. (2005) The not-for-profit form and translational research: Kerr revisited? J. Transl. Med. 3, 19
17. Sonntag, K. C. (2005) Implementations of translational medicine. J. Transl. Med. 3, 33
18. Marincola, E. (2006) Why is public science education important? J. Transl. Med. 4, 7
19. Fontanarosa, P. B., DeAngelis, C. D. and Hunt, N. (2005) Medical research-state of the science. JAMA, J. Am. Med. Assoc. 294, 1424-1425
20. Moskowitz, J. (2005) A not so modest proposal for sustaining the American clinical research enterprise. J. Surg. Res. 125, 117-120
21. Moses, III, H., Dorsey, E. R., Matheson, D. H. and Thier, S. O. (2005) Financial anatomy of biomedical research. JAMA, J. Am. Med. Assoc. 294, 1333-1342
22. Cech, T. R. (2005) Fostering innovation and discovery in biomedical research. JAMA, J. Am. Med. Assoc. 294, 1390-1393
23. Cohen, J. J. and Siegel, E. K. (2005) Academic medical centers and medical research: the challenges ahead. JAMA, J. Am. Med. Assoc. 294, 1367-1372
24. Schechter, A. N., Perlman, R. L. and Rettig, R. A. (2004) Why is revitalizing clinical research so important, yet so difficult? Perspect. Biol. Med. 47, 476-486
25. Cunningham, A. (2006) Changing priorities: Bush initiative shifts science-budget funds. Science News 169, 86
26. Martin, J. B. and Kasper, D. L. (2000) In whose best interest? Breaching the academic-industrial wall. N. Engl. J. Med. 343, 1646-1649
27. AAMC Task Force on Financial Conflicts of Interest in Clinical Research (2003) Protecting subjects, preserving trust, promoting progress II: principles and recommendations for oversight of an institution's financial interests in human subjects research. Acad. Med. 78, 237-245
28. Heffler, S., Smith, S., Keehan, S., Borger, C., Clemens, M. K. and Truffer, C. (2005) U.S, Health Spending Projections For 2004-2014. Health Aff. (Millwood) W5-74-W5-85
29. Snyderman, R. (2004) The AAP and the transformation of medicine. J. Clin. Invest. 114, 1169-1173
30. Jemal, A., Tiwari, R. C., Murray, T. et al. (2004) Cancer statistics, 2004. CA Cancer J. Clin. 54, 8-29
31. Snyderman, R. (2004) The clinical researcher: an 'emerging' species. JAMA, J. Am. Med. Assoc. 291, 882-883
32. Fleischhauer, K., Tanzarella, S., Russo, V. et al. (1997) Functional heterogeneity of HLA-A*02 subtypes revealed by presentation of a MAGE-3-encoded peptide to cytotoxic T cell clones. J. Immunol. 159, 2513-2521
33. (2004) Roadblocks to cancer cures. Nat. Med. 10, 1003
34. Lotze, M. T., Wang, E., Marincola, F. M. et al. (2005) Workshop on cancer biometrics: identifying biomarkers and surrogates of cancer in patients. J. Immunother. 28, 79-119
35. Arteaga, C. L. and Baselga, J. (2003) Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: implications for drug development and practice. Clin. Cancer Res. 9, 1579-1589
36. Conley, B. A. and Taube, S. E. (2004) Prognostic and predictive markers in cancer. Dis. Markers 20, 35-43
37. Hammond, M. E. and Taube, S. E. (2002) Issues and barriers to development of clinically useful tumor markers: a development pathway proposal. Semin. Oncol. 29, 213-221
38. Slingluff, Jr, C. L. and Speiser, D. E. (2005) Progress and controversies in developing cancer vaccines. J. Transl. Med. 3, 18
39. Monsurro', V., Wang, E., Panelli, M. C. et al. (2003) Active-specific immunization against cancer: is the problem at the receiving end? Semin. Cancer Biol. 13, 473-480
40. Marincola, F. M. (2005) A balanced review of the status of T cell-based therapy against cancer. J. Transl. Med. 3, 16
41. Rees, J. (2002) Complex disease and the new clinical sciences. Science 296, 698-700
42. Bialek, W. and Botstein, D. (2004) Introductory science and mathematics education for 21st-century biologists. Science 303, 788-790
43. Jin, P. and Wang, E. (2003) Polymorphism in clinical immunology. From HLA typing to immunogenetic profiling. J. Transl. Med. 1, 8
44. Wang, E., Miller, L. D., Ohnmacht, G. A. et al. (2002) Prospective molecular profiling of subcutaneous melanoma metastases suggests classifiers of immune responsiveness. Cancer Res. 62, 3581-3586
45. Panelli, M. C., Wang, E., Phan, G. et al. (2002) Genetic profiling of peripheral mononuclear cells and melanoma metastases in response to systemic interleukin-2 administration. Genome Biol. 3, RESEARCH0035
46. Wang, E. (2005) RNA amplification for successful gene profiling analysis. J. Transl. Med. 3, 28
47. Wang, E., Panelli, M. C. and Marincola, F. M. (2003) Genomic analysis of cancer. Princ. Pract. Oncol. 17, 1-16
48. Panelli, M. C., White, Jr, R. L., Foster, M. et al. (2004) Forecasting the cytokine storm following systemic interleukin-2 administration. J. Transl. Med. 2, 17
49. Rosenberg, S. A., Yang, J. C. and Restifo, N. P. (2004) Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10, 909-915
50. Mintzberg, H. (1981) Organizational design, fashion or fit? Harvard Business Rev. 59, 103-116
51. Ley, T. J. and Rosenberg, L. E. (2002) Removing career obstacles for young physician-scientists: loan-repayment programs. N. Engl. J. Med. 346, 368-372
52. Ley, T. J. and Rosenberg, L. E. (2005) The physician-scientist career pipeline in 2005: build it, and they will come. JAMA, J. Am. Med. Assoc. 294, 1343-1351
53. Blanco, P., Palucka, A. K., Gill, M., Pascual, V. and Banchereau, J. (2001) Induction of dendritic cell differentiation by IFN-α in systemic lupus erythematosus. Science 294, 1540-1543
54. Woolley, M. and Propst, S. M. (2005) Public attitudes and perceptions about health-related research. JAMA, J. Am. Med. Assoc. 294, 1380-1384